Chronic

Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)

Retrieved on: 
Thursday, September 9, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical Trials

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.
  • Breakthrough Therapy Designation is testament to our commitment to the goal of improving outcomes for people affected by diseases across the cardio-renal-metabolic spectrum.
  • People with left-sided heart failure have either a reduced or a preserved ejection fraction.
  • Ejection fraction is a measurement of the percentage of blood the left ventricle pumps out with each contraction.17 When the heart relaxes, the ventricle refills with blood.

Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Retrieved on: 
Friday, August 27, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical Trials, People, Union, Empagliflozin, European Society of Cardiology, The New England Journal of Medicine, Population, Congress, Blood, Trial, Heart, EMPOWER, Congestion, Gaps, Hospital, Boehringer Ingelheim, Diabetes, European Union, LLY, Research, Heart failure, Hope, Disease, Man, Prevalence, Health, Berlin, Alliance, Death, Fatigue, Lilly, Chronic, SGLT2, NYSE, LVEF, Multimedia, Eli Lilly and Company, Risk, Mortality, Safety, News, ESC, Patient, Kidney disease, Corporation, Cardiovascular disease, Type 2 diabetes, New product development, Woman, Blood volume, Pharmaceutical industry, Medical imaging

This data brings hope for millions of patients suffering from heart failure with a preserved ejection fraction.

Key Points: 
  • This data brings hope for millions of patients suffering from heart failure with a preserved ejection fraction.
  • The risk of death in people with heart failure rises with each hospital admission and with kidney function decline.
  • The landmark EMPEROR-Preserved trial shows that empagliflozin brings significant benefit, which is incredibly exciting and welcome news for both the medical and patient communities.
  • If approved, empagliflozin would become the first clinically proven therapy across the full heart failure spectrum.

Livongo's SIGNUM 2019 Conference Focused on Chronic Condition Solutions

Retrieved on: 
Thursday, February 28, 2019
Medical terminology, Chronic condition, Chronic

SAN FRANCISCO, Feb. 28, 2019 /PRNewswire/ --Livongo, the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced the start of the invitation-only SIGNUM 2019 conference, being held in San Francisco.

Key Points: 
  • SAN FRANCISCO, Feb. 28, 2019 /PRNewswire/ --Livongo, the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced the start of the invitation-only SIGNUM 2019 conference, being held in San Francisco.
  • The conference will also include extensive hands-on, experiential, and small-group sessions to stimulate new connections and approaches to managing chronic conditions.
  • Despite the investment and advances in technology, our healthcare system is failing to adequately address the current chronic condition epidemic.
  • Today, approximately 1801,2 million Americans are suffering from at least one chronic condition and 75 percent of all healthcare industry spending is related to chronic conditions3.

Canadian employers underestimate the proportion of their workforce with a chronic condition and its impact

Retrieved on: 
Wednesday, June 13, 2018
Health, Medical terminology, Medicine, Chronic condition, Disease, Chronic

Three-quarters (77%) of plan sponsors indicate they are concerned about the impact of unmanaged chronic disease on the productivity of their workforce.

Key Points: 
  • Three-quarters (77%) of plan sponsors indicate they are concerned about the impact of unmanaged chronic disease on the productivity of their workforce.
  • A similar proportion of (64%) of plan sponsors are interested in such a service from their benefit carrier.
  • Fifty-eight percent of surveyed plan members report having at least one chronic disease or condition, yet plan sponsors estimate that just 29% of their workforce has a chronic condition.
  • That's changing, and insurers are ramping up the technology to make targeted communications a part of chronic disease management support."